Trifluoperazine

• Description :

  Trifluoperazine, an antipsychotic agent, acts by blocking central dopamine receptors. Trifluoperazine is a potent α1-adrenergic receptor antagonist. Trifluoperazine is a potent NUPR1 inhibitor exerting anticancer activity. Trifluoperazine is a calmodulin inhibitor, and also inhibits P-glycoprotein. Trifluoperazine can be used for the research of schizophrenia. Trifluoperazine acts as a reversible inhibitor of influenza virus morphogenesis[1][2][3][4][5].

• UNSPSC :

  12352005

• Target :

  Adrenergic Receptor; Autophagy; CaMK; Dopamine Receptor; Influenza Virus; P-glycoprotein

• Type :

  Reference compound

• Related Pathways :

  Anti-infection; Autophagy; GPCR/G Protein; Membrane Transporter/Ion Channel; Neuronal Signaling

• Applications :

  COVID-19-anti-virus

• Field of Research :

  Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/trifluoperazine.html

• Purity :

  99.87

• Solubility :

  DMSO : 125 mg/mL (ultrasonic)

• Smiles :

  FC(C(C=C1N2CCCN3CCN(C)CC3)=CC=C1SC4=C2C=CC=C4)(F)F

• Molecular Formula :

  C21H24F3N3S

• Molecular Weight :

  407.50

• References & Citations :

  [1]Santofimia-Castaño P, et al. Ligand-based design identifies a potent NUPR1 inhibitor exerting anticancer activity via necroptosis. J Clin Invest. 2019;129 (6) :2500-2513. Published 2019 Mar 28.|[2]Marques LO, Lima MS, Soares BG. Trifluoperazine for schizophrenia. Cochrane Database Syst Rev. 2004;2004 (1) :CD003545.|[3]Howland RH. Trifluoperazine: A Sprightly Old Drug. J Psychosoc Nurs Ment Health Serv. 2016;54 (1) :20-22.|[4]Huerta-Bahena J, Villalobos-Molina R, García-Sáinz JA. Trifluoperazine and chlorpromazine antagonize alpha 1- but not alpha2- adrenergic effects. Mol Pharmacol. 1983;23 (1) :67-70.|[5]Ochiai H, et al. Influence of trifluoperazine on the late stage of influenza virus infection in MDCK cells. Antiviral Res. 1991;15 (2) :149-160.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C, 3 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• Citation 01 :

  Chem Biol Interact. 2024 Apr 1:392:110904.|Food Biosci. 2024 Feb, 57, 103513.|bioRxiv. 2024 June 12.|BMC Med Genomics. 2024 Jan 2;17 (1) :12.|CNS Neurosci Ther. 2023 Mar;29 (3) :831-841.|Free Radic Biol Med. 2025 Feb 1:227:64-79.|J Transl Med. 2024 Aug 1;22 (1) :715.|Mol Med Rep. 2021 May;23 (5) :319.|Sci Rep. 2025 May 8;15 (1) :16053.

• CAS Number :

  [117-89-5]